Dogwood Therapeutics
Price & Volume
Stats
See more52W Range | $1.28-$9.50 |
Market Cap | $77.8M |
Shares Short | 49,958 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | $1.85 |
News
See moreYahoo Finance • 2 months ago
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Yahoo Finance • 8 months ago
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Yahoo Finance • 10 months ago
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
About
CEO | Mr. Gregory Duncan |
CFO | Ms. Angela Walsh |
Address | 44 Milton Avenue, Alpharetta, GA, United States, 30009 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 8 |